LuPSMA moves UpFront | first RCT data with Arun Azad and Michael Hofman
About this episode
A big day at ESMO in Barcelona today as our friend and colleague A/Professor Arun Azad presents the results of the UpFront PSMA trial for the first time. The data were revealed in the main prostate cancer session at ESMO and simultaneously published in Lancet Oncology. UpFront PSMA is a randomised controlled trial comparing ADT and docetaxel, with ADT + done + LuPSMA in men newly diagnosed high-volume mHSPC. This is a world-first readout of LuPSMA in a prospective randomised trial for mHSPC, and clearly shows a benefit. We dive into the details today with Arun, and another friend and colleague, Professor Michael Hofman, nuc med lead for UpFront PSMA.
This is a Themed Podcast supported by our Silver Partners, Novartis.
Even better on our YouTube channel
Full paper in Lancet Oncology here
Get every episode summarized
Each time GU Cast | Urology Podcast publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.
Email me new episodesFree for 3 shows. No card needed.
Hosts & guests
No transcript yet
This episode has not been transcribed. Request it and it moves to the front of the queue.
More episodes
More from GU Cast | Urology Podcast
Is Copper the new Gold??! Co-PSMA trial in European Urology
GU Cast | Urology Podcast
EAU Prostate Cancer Guideline Update
GU Cast | Urology Podcast
Journal club #7 | proPSMA and Penile Fractures(!)
GU Cast | Urology Podcast
ASPIRE-ing to answer the Triplet question! With Rana McKay and Deepak Kilari
GU Cast | Urology Podcast